Prenuvo
30-Second Executive Brief
Executive Assessment
Prenuvo functions as a regional institution within Healthcare & Life Sciences, backed by 25% sourcing coverage, with a stable competitive position.
- Maintains 2 mapped relationships across the graph
- 25% sourcing coverage across sourced relationships
- Tracked as regional institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Regional Institution
- Sourcing Coverage
- 25%
- Ecosystem Influence
- Moderate
- Strategic Momentum
- Insufficient Data
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 2
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A whole-body MRI screening company offering biomarker testing, brain-health assessment and body-composition analysis, having conducted over 130,000 scans as of May 2025 with roughly $275M raised — a comparable diagnostics-forward preventive-health platform to Lifecore's own offering.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- CB Insights — Prenuvo passes 130,000 whole-body MRI scansresearch
- PitchBook — Prenuvo Series C funding round and valuationresearch
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Prenuvo — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Prenuvo's valuation-to-funding ratio suggests more conservative investor pricing than Neko Health's celebrity-backed round
38% confidencePrenuvo's roughly $600 million valuation against $275 million raised (about a 2.2x multiple) is far more modest than Neko Health's nearly $7 billion valuation on a comparable full-body-scan business model, which may reflect Prenuvo's narrower MRI-centric positioning versus Neko's broader AI-diagnostics platform and celebrity investor base, though the two rounds occurred roughly 18 months apart under different market conditions.
This comparison is InsightNodes' own analytical read combining separately reported valuation figures at different points in time; it is not a conclusion stated by either company, and differing round timing/market conditions limit how directly comparable the two multiples really are.
InsightNodes analysis of PitchBook and Axios funding data · Aug 13, 2026
Prenuvo's Timeline
A sourced, dated history of Prenuvo's key moments — founding to present.
Feb 2025 · Raises $120M Series C led by Forerunner Ventures
Prenuvo raised a $120 million Series C round led by Forerunner Ventures, its largest round to date, bringing total funding to roughly $275 million at a valuation of approximately $600 million.